First-in-human phase 1 dose escalation and expansion of a novel combination, anti-CSF-1 receptor (cabiralizumab) plus anti-PD-1 (nivolumab), in patients with advanced solid tumors - Wainberg, Z; Piha-Paul, S; Luke, J (J Immunother Cancer, 2017)
(Suppl 3):